We are live on
!
Find out more
PP
Palladium Partners Portfolio holdings
AUM
$2.28B
1-Year Est. Return
12.96%
This Fund
S&P 500
This Quarter
Est. Return
+1.78%
1 Year Est. Return
+12.96%
3 Year Est. Return
+64.31%
5 Year Est. Return
+102.3%
10 Year Est. Return
–
AUM
$1.17B
AUM Growth
+$13.7M
(+1.2%)
Cap. Flow
+$3.13M
Cap. Flow
% of AUM
0.27%
Top 10 Holdings %
Top 10 Hldgs %
23.42%
Holding
261
New
6
Increased
53
Reduced
155
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$4.26M |
| 2 |
Gilead Sciences
GILD
|
+$4.2M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$2.63M |
| 4 |
WisdomTree Emerging Markets SmallCap Dividend Fund
DGS
|
+$2.04M |
| 5 |
AGN
Allergan plc
AGN
|
+$1.93M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$3.27M |
| 2 |
Comcast
CMCSA
|
+$2.58M |
| 3 |
BP
BP
|
+$1.61M |
| 4 |
Procter & Gamble
PG
|
+$1.37M |
| 5 |
IBM
IBM
|
+$1.16M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 13.12% |
| 2 | Financials | 11.75% |
| 3 | Healthcare | 11.15% |
| 4 | Industrials | 10.1% |
| 5 | Consumer Staples | 8.61% |
Similar funds
ACM
ACI
BAM
SCC
IA
MXM
OSIA
MAM
Palladium Partners's Q1 2015 Portfolio in Review
As of Q1 2015, Palladium Partners held 261 positions worth $1.17B, up 1.2% from $1.15B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Palladium Partners's Q1 2015 filing shows 6 new, 53 increased, 155 reduced and 9 closed positions. Its largest new stake was Vanguard Morningstar Large-Cap ETF: 6,567 shares worth $625K. The largest sale was Amgen, an estimated $3.27M.
By sector, the portfolio is most concentrated in Technology at 13% of assets, down from 13% a quarter earlier, followed by Financials and Healthcare.
- Palladium Partners's largest Q1 2015 buy was Vanguard Morningstar Large-Cap ETF: 6,567 shares worth $625K.
- Palladium Partners added most to Vanguard FTSE Developed Markets ETF in Q1 2015, an estimated $4.26M increase.
- Palladium Partners's biggest Q1 2015 reduction was Amgen, cutting an estimated $3.27M.
- Palladium Partners fully exited Teva Pharmaceuticals in Q1 2015, selling an estimated $431K.
- Palladium Partners's ten largest holdings make up 23% of its $1.17B portfolio in Q1 2015.
- Palladium Partners opened 6 new positions and closed 9 in Q1 2015.
- Palladium Partners's portfolio value rose 1.2% quarter-over-quarter to $1.17B.
Based on Palladium Partners's 13F filing for Q1 2015, filed 11 May 2015.